Month: September 2026

New York, Sept. 11, 2026 (GLOBE NEWSWIRE) — Columbus Acquisition Corp (the “Company”), a blank check company, today announced that it convened its Extraordinary General Meeting of the Shareholders (the “Meeting”) and immediately adjourned the Meeting, without conducting any business.

The Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on August 19, 2026, including any amendments or supplements thereto (the “Proxy Statement”), including the proposal to approve the proposed business combination with WISeSat.Space Corp.

The Company will announce the date of the reconvened Meeting, and a new redemption deadline (the “Extended Redemption Deadline”), in the coming days. Public shareholders seeking to exercise their redemption rights must complete the procedures described in the Proxy Statement by the Extended Redemption Deadline. As of September 8, 2026, there was approximately $10.66 per share in trust.

The record date for determining the Company shareholders entitled to receive notice of and to vote at the Meeting remains the close of business on August 17, 2026 (the “Record Date”). Shareholders as of the Record Date are eligible to vote, even if they have subsequently sold their shares.
  
If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal.

If you have already submitted a proxy and do not wish to change your vote, you need not take any further action. If you have submitted a proxy and wish to change your vote, you may revoke your proxy at any time before it is exercised at the Meeting as provided in the Proxy Statement. Please note, however, that if your shares are held in street name by a broker or other nominee and you wish to revoke a proxy, you must contact the broker or nominee to revoke any prior voting instructions.

The Company’s shareholders who have questions regarding the adjournment, or the Meeting, or would like to request documents may contact the Company’s proxy solicitor, Advantage Proxy, Inc., at:

Advantage Proxy, Inc. P.O. Box 10904
Yakima, WA 98909
Individuals call toll-free 1-877-870-8565
Banks and brokers call 1-206-870-8565
Email: ksmith@advantageproxy.com

In addition, shareholders who have already submitted a redemption request with respect to the shares held by them may withdraw such request by contacting our transfer agent. If you would like to change or revoke your prior vote on any proposal, or reverse a redemption request, please refer to the Proxy Statement for additional information on how to do so.

In connection with the adjournment of the Meeting and the extension of the redemption deadline, the Company is concurrently filing with the Securities and Exchange Commission (“SEC”) definitive additional materials on Schedule 14A, consisting of a supplement dated September 11, 2026 (the “Supplement”) to the Proxy Statement. Shareholders are encouraged to read the Supplement together with the Proxy Statement.

About Columbus Acquisition Corp

Columbus Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Columbus is led by Fen “Eric” Zhang, Chairman and Chief Executive Officer, and Jie “Janet” Hu, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries. 

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including but not limited to the date of the Meeting, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Additional Information and Where to Find It

On August 19, 2026, the Company filed a definitive proxy statement with the SEC in connection with its solicitation of proxies for the Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the website maintained by the SEC at www.sec.gov or by contacting the Company’s proxy solicitor.

Participants in the Solicitation

The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above.

Contact

Fen Zhang
Chairman and Chief Executive Officer
Email: eric.zhang@herculescapital.group
Tel: (+1) 949 899 1827 

SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE^® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE^® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.

The webinar will feature Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, and Dr. Jeffrey Miller, MD¹, Consulting Senior Medical Director, who will discuss clinical progress in blood cancers and solid tumors, insights from increasing dose levels, the platform’s competitive positioning, and key milestones ahead.

Webinar Information:
Title: The TriKE^® Platform, Clinical Progress, and the Case for NK Cell Immunotherapy
Date: Friday, September 11, 2026
Time: 2:00 p.m. Eastern Time
Webcast: Please click here to register.

A replay of the webcast will be made available at gtbiopharma.com following the event.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE^® NK cell engager platform. Our TriKE^® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE^® technology. For more information, please visit gtbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,” or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.

TriKE^® is a registered trademark owned by GT Biopharma, Inc.

Investor Relations Contact:

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577

LinkedIn |Facebook |X |Instagram | YouTube

¹ Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.

$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants

BRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock (or pre-funded warrant in lieu thereof), series C warrants to purchase up to 3,105,591 shares of common stock and series D warrants to purchase up to 3,105,591 shares of common stock, at a combined purchase price of $0.805 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement. The series C warrants and the series D warrants will have an exercise price of $0.805 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The series C warrants will expire six years from the later of the Stockholder Approval Date and the Effectiveness Date (as defined below) and the series D warrants will expire three years from the later of the Stockholder Approval Date and the Effectiveness Date. The private placement is expected to close on or about September 14, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering are expected to be approximately $2.5 million, prior to deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series C warrants and the series D warrants, if fully exercised on a cash basis, will be approximately $5 million. No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The securities described above are being offered in a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement, the Company has agreed to file a registration statement covering the resale of the common stock (or the shares of common stock issuable upon exercise of the pre-funded warrant in lieu thereof) issued in the private placement and the shares of common stock issuable upon exercise of the warrants issued in the private placement (the date of effectiveness of such registration statement, the “Effectiveness Date”).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest’s lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: the consummation of the offering and the satisfaction of customary closing conditions related to the private placement, the use of proceeds therefrom, the potential exercise of the warrants and the receipt of Stockholder Approval. All forward-looking statements in this press release are based on Tempest’s current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to the market and other conditions, Tempest’s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest.

Investor Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Hong Kong, Sept. 11, 2026 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “Click” or “we” or “us”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), a leader in human resources (“HR”) and senior care solutions in Hong Kong, today announced that its Chief Executive Officer (“CEO”), Mr. Chan Chun Sing, has purchased 48,200 Class A ordinary shares of the Company in the open market.

Purchase Details

Mr. Chan acquired a total of 48,200 Class A ordinary shares of Click in the open market. All purchases were made at prevailing market prices, representing an aggregate investment of approximately US$49,900. For full details, please refer to the Form 4 filed with the U.S. Securities and Exchange Commission.

“These purchases reflect my personal commitment to the Company and to long-term value creation for shareholders,” said Mr. Chan, CEO of Click. “We remain focused on executing our plan in senior care, nursing, logistics and AI-powered HR solutions, while supporting the Company’s previously announced long-term strategy targeting approximately HK$500 million in annual revenue.”

The Company continues to focus on organic growth, strategic initiatives and operational performance, and remains open to additional mergers and acquisitions and cooperation MOUs to support its service offerings, market position and long-term strategy targeting approximately HK$500 million in annual revenue.

The Company expects to announce its annual results for the fiscal year ended June 30, 2026 in October 2026, in accordance with applicable reporting requirements. This press release does not contain financial results, forecasts or guidance.

About Click Holdings Limited (NASDAQ: CLIK)

Click Holdings Limited (NASDAQ: CLIK) is a Hong Kong-based leader in AI-powered human resources and senior care solutions. Through its proprietary platform, CLIK connects clients with a talent pool of over 25,000 professionals, serving nursing, logistics, and professional services sectors.

For more information, please visit https://clickholdings.com.hk.

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For enquiry, please contact:

Click Holdings Limited

Unit 1709-11, 17/F
Tower 2, The Gateway
Harbour City, Kowloon
Hong Kong
Email: jack.wong@jfy.hk
Phone: +852 2691 8200 

New Location Marks 17th Store in Denver Area

Scottsdale, AZ, Sept. 11, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, the Oregon-born boutique coffee chain celebrated for its specialty coffees, teas, smoothies, and signature Fuel® energy drinks, is growing its footprint in Colorado with the opening of a new store in Highlands Ranch. 

The store, located at 9401 S University Blvd, will officially open its doors on Monday, September 14th. This opening marks Black Rock’s twenty-second Colorado location and reinforces the brand’s steady expansion across the region. Guests can enjoy the following specials during opening week: 

• Monday, 9/14: Free 16oz Drinks 

• Tuesday, 9/15: Buy One, Get One Free Drinks 

• Wednesday, 9/16: 50% Off a Drink w/ Food Purchase 

• Thursday, 9/17: Free Signature Grand Opening Sticker with purchase while supplies last 

• Friday, 9/18: Free T-Shirt with purchase while supplies last 

• Saturday, 9/19: $2 Off Any Size Drink 

“Each new store gives us the opportunity to become part of a new community, and we’re excited to continue growing in Colorado,” said Mark Davis, CEO of Black Rock Coffee Bar. “We’re thrilled to open new doors in Highlands Ranch and look forward to building relationships with local guests while bringing them the drinks, service, and energy that make Black Rock unique.”  

Guests can also take advantage of the Black Rock Rewards app, where every purchase—whether in-store, online, or through the app—earns “bolts” that can be redeemed for free beverages. Recent menu additions, like Black Rock’s protein-packed Egg Bites, are also included in the program. 

Black Rock Coffee Bar is beloved for its handcrafted beverages, including the Caramel Blondie, a sweet and creamy signature blend; the Mexican Mocha, a spicy twist with hints of vanilla, almond, and cinnamon; and the Jackhammer, a vanilla mocha with an extra double shot; as well as its in-house developed Fuel energy drink, customizable with over 20 fruit flavors.  These can be enjoyed alongside sweet and savory food items, including the recently launched Grilled Cheese and Pumpkin Blondie Cake Pop. For an extra kick of protein, guests can add Black Rock’s new Protein Cold Foam, Protein Boosted Milk or Protein Boost to their drinks. 

 

In addition to Black Rock menu staples, guests can enjoy limited-time offerings like the Pumpkin Spiced Latte, Pumpkin Blondie, and Pumpkin Spice Cookie Latte with Cookie Butter Cold Foam. The brand’s Fall Remix seasonal drinks are also now available, featuring the Caramel Apple Butter Shaken Espresso, Cinnamon Bun Latte, and Spellbound Berry Fuel, offering a mix of nostalgic and refreshing flavors. 

For more information, visit https://br.coffee/ and follow @blackrockcoffeebar on Facebook and Instagram, and @blackrockcoffeeofficial on TikTok for updates on new locations, promotions, and seasonal offerings. 

 

About Black Rock Coffee Bar  

Black Rock Coffee Bar is a national boutique coffee shop that is known for its premium roasted coffees, teas, smoothies and flavorful Fuel® energy drinks. Founded as a family owned and operated business in Oregon in 2008, Black Rock Coffee Bar has grown to over 200 retail locations in seven states. The Black Rock culture prides itself on not only being a positive force for the communities it serves, but also the team members that fuel their locations day in and day out. An important aspect of their team mission is to recognize those that go above and beyond by displaying the 4G’s of Black Rock – grit, growth, gratitude, and grace. For more information, visit https://br.coffee/.  

Attachments

• Black Rock Coffee Bar
• Black Rock Coffee Bar

CONTACT: Audrey Arbogast
Black Rock Coffee Bar
audrey.arbogast@havasred.com

McQueen & Queen Creek Rd Location to Celebrate Grand Opening on September 15th

Scottsdale, AZ, Sept. 11, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, the Oregon-born boutique coffee company known for its specialty coffees, teas, smoothies, and popular Fuel® energy drinks, is expanding its footprint in the Valley with a new location opening this week. 

The store, located at 3103 S McQueen Rd, will officially celebrate its grand opening in Chandler on Tuesday, September 15th. Guests can enjoy $3 medium drinks all day, with the celebration continuing into the following day with a signature grand opening sticker giveaway. With this opening, Black Rock’s Arizona presence grows to 62 locations, underscoring the brand’s steady expansion throughout the Valley.  

“We’ve seen tremendous momentum across the valley, and we’re excited to build on that with our newest location in Chandler,” said Mark Davis, CEO of Black Rock Coffee Bar. “Our team is ready to welcome guests and make this location a go-to spot for their daily coffee, fuel, and connection.” 

Guests can also take advantage of the Black Rock Rewards app, where every purchase—whether in-store, online, or through the app—earns “bolts” that can be redeemed for free beverages. Recent menu additions, like Black Rock’s protein-packed Egg Bites, are also included in the program. 

Black Rock Coffee Bar is beloved for its handcrafted beverages, including the Caramel Blondie, a sweet and creamy signature blend; the Mexican Mocha, a spicy twist with hints of vanilla, almond, and cinnamon; and the Jackhammer, a vanilla mocha with an extra double shot; as well as its in-house developed Fuel energy drink, customizable with over 20 fruit flavors.  These can be enjoyed alongside sweet and savory food items, including the recently launched Grilled Cheese and Pumpkin Blondie Cake Pop. For an extra kick of protein, guests can add Black Rock’s new Protein Cold Foam, Protein Boosted Milk or Protein Boost to their drinks. 

 In addition to Black Rock menu staples, guests can enjoy limited-time offerings like the Pumpkin Spiced Latte, Pumpkin Blondie, and Pumpkin Spice Cookie Latte with Cookie Butter Cold Foam. The brand’s Fall Remix seasonal drinks are also now available, featuring the Caramel Apple Butter Shaken Espresso, Cinnamon Bun Latte, and Spellbound Berry Fuel, offering a mix of nostalgic and refreshing flavors.  

For more information, visit https://br.coffee/ and follow @blackrockcoffeebar on Facebook and Instagram, and @blackrockcoffeeofficial on TikTok for updates on new locations, promotions, and seasonal offerings. 

 

About Black Rock Coffee Bar  

Black Rock Coffee Bar is a national boutique coffee shop that is known for its premium roasted coffees, teas, smoothies and flavorful Fuel® energy drinks. Founded as a family owned and operated business in Oregon in 2008, Black Rock Coffee Bar has grown to over 200 retail locations in seven states. The Black Rock culture prides itself on not only being a positive force for the communities it serves, but also the team members that fuel their locations day in and day out. An important aspect of their team mission is to recognize those that go above and beyond by displaying the 4G’s of Black Rock – grit, growth, gratitude, and grace. For more information, visit https://br.coffee/.  

Attachments

• Black Rock Coffee Bar
• Black Rock Coffee Bar

CONTACT: Audrey Arbogast
Black Rock Coffee Bar
audrey.arbogast@havasred.com

Management to Hold One-on-One Meetings with Institutional Investors

SINGAPORE, Sept. 11, 2026 (GLOBE NEWSWIRE) — BGIN BLOCKCHAIN LIMITED (“BGIN” or the “Company”; NASDAQ: BGIN), a digital asset technology company specializing in proprietary cryptocurrency mining technologies and the manufacturing of cryptocurrency mining hardware, today announced that members of its management team will participate in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

Management will also be available for one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with the Company should contact their H.C. Wainwright representative or BGIN’s investor relations team at ir@bgin.com.

About BGIN BLOCKCHAIN LIMITED

BGIN BLOCKCHAIN LIMITED (NASDAQ: BGIN) is a digital asset technology company with proprietary cryptocurrency-mining technologies that leverages its experience in designing ASIC chips and mining machines to penetrate new cryptocurrency opportunities and execute on a long-term strategic focus on self-mining. BGIN’s mission is to make crypto mining accessible to all by developing innovative products tailored to various market needs, from beginners to large-scale industrial miners. BGIN designs and manufactures mining machines under its ICERIVER brand, providing customers with operational flexibility through advanced mining infrastructure and hosting services.

For more information, please visit: www.bgin.com or www.iceriver.io, or follow BGIN on X @Bgin_Blockchain and LinkedIn @BGIN, and follow ICERIVER® on X @IceRiverMiner.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” “target,” “project,” “potential,” “seek,” “may,” “should,” “could,” “would,” and similar expressions or the negative thereof. Statements that are not historical facts, including but not limited to statements regarding the Company’s participation in investor conferences, management’s availability for meetings with institutional investors, and the Company’s strategic plans and objectives, are forward-looking statements. Although BGIN believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and BGIN cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in BGIN’s filings with the U.S. Securities and Exchange Commission (the “SEC”). Additional factors are discussed in BGIN’s filings with the SEC, which are available for review at www.sec.gov. All information provided in this press release is as of the date of this press release, and BGIN does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

BGIN BLOCKCHAIN LIMITED

Investor Relations
Jennifer Jiang
ir@bgin.com

Media Relations
Ray Xie
pr@bgin.com

VANCOUVER, British Columbia, Sept. 11, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) announces the completion of an initial geological reconnaissance programme across its critical minerals portfolio in northern Bahia, southern Bahia and Ceará, Brazil.

Together, the three land packages cover approximately 123,900 hectares within established and emerging critical minerals provinces. The reconnaissance programme confirmed geological settings supporting further evaluation for Cu-Ni-Co and rare earth elements (“REE”) in northern Bahia and lithium exploration in southern Bahia and Ceará.

Highlights

• Initial geological reconnaissance confirmed geological settings relevant to Cu-Ni-Co and REE exploration in northern Bahia and lithium exploration in southern Bahia and Ceará.
• In northern Bahia, field observations identified mafic rocks for Cu-Ni-Co evaluation and magnetic, potassium-rich rocks within the Itiúba Syenitic Massif, a geological setting considered favourable for REE-Nb-Zr-Y exploration.
• Coarse-grained pegmatites were identified within selected tenements in southern Bahia and Ceará, providing priority areas for follow-up lithium exploration.
• GoldHaven’s three Brazilian land packages cover approximately 123,900 hectares within established and emerging critical minerals provinces.
• Rock samples have been submitted for laboratory analysis, with results to be used to refine exploration priorities and guide focused follow-up work.

CEO Commentary

Rob Birmingham, President and CEO of GoldHaven, commented:

“This programme accomplished exactly what we set out to do — rapidly evaluate a large land position and identify the geological environments that warrant further investment. Across approximately 123,900 hectares, we have identified areas for focused Cu-Ni-Co and rare earth evaluation in northern Bahia, together with coarse-grained pegmatites warranting follow-up for lithium potential in southern Bahia and Ceará.”

“With samples now at the laboratory, the results will help us prioritize the strongest opportunities and determine where we focus our next phase of exploration.”

Geological Reconnaissance Programme

The reconnaissance programme was designed to test the initial geological interpretations across GoldHaven’s Brazilian critical minerals portfolio, confirm the occurrence of relevant geological environments and establish an initial order of priority for follow-up exploration.

Given the scale of the land packages, an important objective was to rapidly screen the properties, deprioritize areas considered less prospective and concentrate future geological work and exploration expenditure on the most prospective areas.

Field activities included geological reconnaissance, verification of regional geological interpretations, examination of available outcrops and the collection of representative rock samples. Samples have been submitted for laboratory analysis, with results pending.

Figure 1. Location map of the GoldHaven tenements

Northern Bahia – Cu-Ni-Co and Rare Earth Targets

GoldHaven’s northern Bahia land package covers approximately 41,400 hectares and supports the evaluation of two distinct exploration concepts: Cu-Ni-Co and REE-Nb-Zr-Y.

The properties cover portions of the Caraiba granulitic terrain, including areas containing mafic to locally ultramafic rocks, and the Itiúba Syenitic Massif, where magnetic and potassium-rich syenitic rocks provide a favourable geological setting for REE-Nb-Zr-Y exploration.

The Cu-Ni-Co concept is associated with mafic and ultramafic rocks. Tenements 871.601/2024, 871.578/2024, 871.590/2024 and 871.597/2024 have been selected for initial follow-up based on the recognition of mafic rocks during fieldwork, including bedrock exposures. Laboratory analysis and focused geological mapping will be used to assess the composition and distribution of these rocks.

The REE-Nb-Zr-Y concept is associated with syenitic and other alkaline to felsic rocks. Tenements 871.596/2024, 871.593/2024, 871.595/2024 and 871.594/2024 have been selected for initial follow-up based on their position within the Itiúba Syenitic Massif and the occurrence of magnetic and potassium-rich rocks. Laboratory analysis will be required to assess their geochemical characteristics and relevance to REE-Nb-Zr-Y exploration.

The field programme included the collection of 13 rock samples.

Figure 2. Northern Bahia Project showing GoldHaven’s tenements and the distribution of rock types identified during the initial geological reconnaissance programme.

Southern Bahia – Coarse-Grained Pegmatite Occurrences

GoldHaven’s southern Bahia land package covers approximately 30,700 hectares within a geological environment relevant to lithium exploration.

Field reconnaissance confirmed the presence of coarse-grained pegmatites within tenements 871.606/2024 and 871.607/2024, which have been selected for initial LCT follow-up. The properties are located within a regional geological environment containing paragneisses, metasedimentary rocks, muscovite-bearing rocks and granitic intrusions. Historical occurrences of beryl, niobium and gem-bearing pegmatites are also reported in the region.

The pegmatites observed within the two tenements occur within metasedimentary host rocks. Follow-up work will include geochemical analysis, mineralogical studies and more detailed pegmatite mapping.

Tenement 871.610/2024 remains a secondary follow-up area based on pegmatitic and muscovite-rich altered rocks recognized during the reconnaissance programme.

The presence of coarse-grained pegmatites alone does not establish LCT fertility. Laboratory analysis and mineralogical studies are required to determine their composition and exploration significance.

Figure 3. Southern Bahia Project showing GoldHaven’s tenements and the distribution of rock types identified during the initial geological reconnaissance programme.

Figure 4. Coarse pegmatites identified in Southern Bahia

Ceará (Iguatu) – Pegmatite Occurrences

GoldHaven’s Ceará land package covers approximately 51,800 hectares within and near the Solonópole Pegmatite Sub province, a geological setting relevant to the evaluation of LCT pegmatites.

Field reconnaissance confirmed the presence of coarse-grained pegmatites within tenements 801.099/2023, 801.119/2023 and 801.115/2023, which have been selected for initial LCT follow-up. The properties are located mainly within the Acopiara Complex and near the Solonópole Pegmatite Sub province.

The pegmatites observed within these three tenements locally contain muscovite and occur in granitic and metasedimentary geological environments. Follow-up work will include geochemical analysis, mineralogical studies and more detailed mapping.

Pegmatite veins and outcrops were also identified within tenements 801.102/2023, 801.108/2023, 801.120/2023 and 801.117/2023. Their relative priority will be assessed following receipt and interpretation of the analytical results.

The field programme included the collection of 19 rock samples.

Figure 5. Ceará Project showing GoldHaven’s tenements and the distribution of rock types identified during the initial geological reconnaissance programme.

Figure 6. Coarse pegmatite outcrop, Ceará tenements

Samples at Laboratory and Next Steps

Rock samples collected during the reconnaissance programme have been submitted for laboratory analysis. Results will be used to refine exploration priorities and guide follow-up work.

The analytical programme includes:

• Cu, Ni, Co, Cr, V, Sc, Au, Ag and platinum-group elements for mafic and ultramafic rocks;
• REE, Nb, Ta, Zr, Hf, Y, Th, U, Ga and relevant major elements for syenitic and felsic rocks; and
• Li, Cs, Rb, Ta, Nb, Sn, Be, B, Ga, Ge, W and complete REE analysis for pegmatites.

Once received, the analytical results will be integrated with field observations and regional geological information. Interpretation will consider multi-element associations and geological context rather than individual anomalous values.

The results will be used to refine the current exploration priorities and determine where focused geological mapping, mineralogical studies and additional sampling are warranted. In northern Bahia, follow-up work may assess the distribution of mafic to ultramafic rocks and selected portions of the Itiúba Syenitic Massif. In southern Bahia and Ceará, follow-up work may focus on the composition, distribution and geological controls of the identified pegmatites.

GoldHaven will provide a further update once the analytical results have been received and interpreted.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jonathan Victor Hill, B.Sc. (Hons), FAusIMM, a Qualified Person as defined by National Instrument 43-101 and Country Manager of GoldHaven Resources Corp. Mr. Hill is not independent of the Company.

Investor Awareness

GoldHaven has engaged PanAm Marketing Inc. (“PanAm”) to provide digital investor awareness and marketing services, including digital advertising, content development and coordination with third-party publishers and content creators across online advertising networks, financial and investment websites, social media platforms and email newsletters. The engagement is for an initial three-month term commencing September 11^th, 2026 and ending December 11^th 2026, for a total campaign budget of $300,000 payable in cash. No securities, options, warrants or performance-based compensation are payable. PanAm is arm’s length to the Company and, to the Company’s knowledge, neither PanAm nor its principals currently hold any securities of GoldHaven. PanAm’s contact information is: Jeff Leslie, 5728 East Blvd., Vancouver, BC V6M 4M4; accounts@panam.marketing; 780-257-4680.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• The expectation that laboratory analysis of the rock samples collected during the reconnaissance programme will be used to refine exploration priorities and guide follow-up work
• GoldHaven’s plans for follow-up work in northern Bahia, including geological mapping and laboratory analysis to assess the composition and distribution of mafic to ultramafic rocks and rocks within the Itiúba Syenitic Massif
• GoldHaven’s plans for follow-up work in southern Bahia and Ceará, including geochemical analysis, mineralogical studies and more detailed pegmatite mapping
• The expectation that analytical results will be integrated with field observations and regional geological information to determine where focused geological mapping, mineralogical studies and additional sampling are warranted
• GoldHaven’s intention to provide a further update once the analytical results have been received and interpreted

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/a9ac10ec-a6a9-4aa0-a7d0-fd17aae54d33

https://www.globenewswire.com/NewsRoom/AttachmentNg/342df922-454d-4603-b805-9428f76b95de

https://www.globenewswire.com/NewsRoom/AttachmentNg/78d70fa5-fb8a-41f5-9ee1-eb39693afbff

https://www.globenewswire.com/NewsRoom/AttachmentNg/c9badab4-4784-4953-818f-a6f4440b0c1f

https://www.globenewswire.com/NewsRoom/AttachmentNg/3375ad51-32f4-49c4-aabb-cec6c961fd24

https://www.globenewswire.com/NewsRoom/AttachmentNg/84d046e4-0573-4bc1-a8e9-df5eabe398c4

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary psychedelic-based treatment candidate for AUD.

The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first time CMND-100 is administered to a patient with AUD. To date, the Company has evaluated CMND-100 at multiple doses in healthy participants as part of its clinical development program.

“Our enrollment trajectory continues to build positively and treating the first Alcohol Use Disorder patients with CMND‑100 represents a major step forward,” said Adi Zuloff‑Shani, Ph.D., Chief Executive Officer of Clearmind. “This achievement highlights the growing momentum behind the program and positions us well as we progress toward key clinical milestones that we believe can drive meaningful value for shareholders.

The clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with Alcohol Use Disorder.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated progress of the CMND-100 clinical trial, the achievement of future clinical milestones, the potential safety, tolerability, pharmacokinetic and efficacy results of CMND-100, the continued enrollment of patients in the trial, the development and commercialization potential of CMND-100, and the potential value that the program may create for shareholders. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

• Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma (HNSCC) in patients with negative PD-L1 expression (Combined Positive Score (CPS) < 1) and the neoadjuvant setting of soft tissue sarcoma (STS).
• Root cause analysis following the discontinuation of TACTI-004 has identified subtle analytical differences between efti manufactured at 200 L scale and efti manufactured at 2,000 L scale. A new manufacturing run of efti at 200 L scale has been contracted.
• This development focus reflects a staged risk/benefit approach consistent with prior interactions with the U.S. Food and Drug Administration (FDA), Orphan Drug Designation granted for STS in April 2026, and Fast Track designation for HNSCC.
• Preparations for the next clinical trials have commenced, with study start targeted for 2H CY2027, subject to final decisions on trial design, regulatory interactions, manufacturing timelines, partnering and resources.

SYDNEY, AUSTRALIA, Sept. 11, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today provides an update on its development strategy for eftilagimod alfa (“efti”).

Update on Root Cause Analysis
Following the early discontinuation of the TACTI-004 study, Immutep has been conducting a detailed root cause analysis covering clinical, pharmacological and manufacturing aspects. This ongoing root cause analysis has identified structural differences between the efti used in TACTI-004 and the efti used in earlier successful clinical studies. These differences (e.g. a subtle difference in N-glycan structure) are considered potentially relevant given the markedly different immune activation profile observed in TACTI-004 compared to previous trials and the unexpected clinical outcome of the study.

Based on the currently available data from the Root Cause Analysis to date, Immutep believes that the unexpected outcome of TACTI-004 cannot be explained by clinical factors (e.g. suboptimal protocol, substantial imbalance between treatment arms or safety findings) or trial execution factors (e.g. invalid randomisation pattern or general clinical trial conduct). The Company will provide a further update on completion of the root cause analysis.

New Manufacturing Run
Based on the findings from the root cause analysis to date, Immutep has contracted a manufacturing run of efti at 200 L scale. Ten GMP batches of efti have previously been manufactured at 200 L scale and used in successful Phase I and Phase II clinical studies of efti, including TACTI-mel, TACTI-002 and INSIGHT-003. In contrast, TACTI-004 was conducted exclusively with efti manufactured at 2,000 L scale.

Future Clinical Development Focus
Immutep currently intends to focus the registration-directed clinical development of efti on:

• HNSCC in patients with CPS < 1 — based on clinical efficacy data, including mature overall survival data, in a patient population with high unmet need and limited approved treatment options, and for which efti has received Fast Track designation and FDA feedback that the Company considers constructive; and
• the neoadjuvant setting of STS — based on positive Phase II data, including achievement of the primary endpoint, and for which efti received Orphan Drug Designation from the FDA in April 2026.

This focus reflects the compelling clinical data generated to date, the Company’s interactions with the FDA, regulatory designations obtained, unmet medical need and substantial market potential in these indications.

Preparations for the next clinical trials have commenced. Subject to final decisions on strategy and trial design, regulatory interactions, manufacturing timelines, partnering and resources, Immutep is targeting study start during 2H CY2027.

Immutep’s licensing partner, Dr. Reddy’s Laboratories (“DRL”), has been consulted on and is supportive of this approach. The Company is also in preliminary discussions with other parties regarding the proposed development pathway.

Immutep CEO, Marc Voigt, said: “Based on the totality of evidence generated with efti, we believe there is a scientifically and clinically justified path to continue its development. This includes clinical and translational data across multiple tumour types, consistent evidence of immune activation, encouraging results in soft tissue sarcoma and head and neck cancer with CPS < 1, and constructive regulatory interactions. At the same time, we fully recognise the significance of the TACTI-004 outcome. Our root cause analysis remains ongoing, including further investigation of smaller differences identified between product batches. We intend to apply these learnings rigorously and focus future potential development on settings where the clinical evidence, biological rationale, time-to-market and unmet medical need are most compelling.”

Other Programs
Immutep’s LAG-3 portfolio extends beyond efti. Development of IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune disease, continues in line with previously disclosed plans.

About Eftilagimod Alfa (Efti)
Efti is a novel immunotherapy that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class II pathway to fight cancer. As an MHC Class II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important co-stimulatory signals and cytokines that further boost the immune system’s ability to combat cancer.

Efti’s favourable safety profile has enabled various combinations, including with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy. Efti has received Fast Track designation in 1st line HNSCC and in 1st line NSCLC, and Orphan Drug Designation in STS, from the United States Food and Drug Administration (FDA).

About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa (efti) and IMP761. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, the ongoing root cause analysis, manufacturing, the ability to reach agreement with regulators on trial design and registrational pathways, the outcome of partnering discussions, and the Company’s ability to obtain additional funding and to advance its product candidates. Additional risks are described in the Company’s most recent Annual Report on Form 20-F and subsequent filings with the U.S. Securities and Exchange Commission and in announcements lodged with the ASX. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415 1750; matthew.beck@astrpartners.com